Treatment of systematic sporotrichosis with ketoconazole

David L. Calhoun, Hetty Waskin, Michael P. White, James R. Bonner, John H. Mulholland, Larry W. Rumans, David A. Stevens, John N. Galgiani

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Infections of deep soft tissues with the dimorphic fungus Sporothrix schenckiiare uncommon in humans, and therapy has often required toxic drugs. We report our experience in treating 11 patients who had deep-seated sporotrichosis with ketoconazole, a well-tolerated, orally absorbed antifungal agent. Eight infections involved one or more joints, and three involved thoracic, cervical, and widespread cutaneous sites, respectively. For eight patients all evidence of infection resolved during therapy. Sustained remissions (6 months to 5 years) were noted for six patients after the discontinuation of all therapy and for an additional patient 4 years after the initiation of ketoconazole treatment. Durable responses were associated with prolonged treatment with 400-800 mgofketoconazole daily.Our favorableexperience suggeststhat oral therapy with ketoconazole may benefit other patients with systemic sporotrichosis.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalReviews of infectious diseases
Issue number1
StatePublished - Jan 1990

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Treatment of systematic sporotrichosis with ketoconazole'. Together they form a unique fingerprint.

Cite this